Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Autocrine signaling in carcinoma: VEGF and the alpha6beta4 integrin.

Mercurio AM, Bachelder RE, Bates RC, Chung J.

Semin Cancer Biol. 2004 Apr;14(2):115-22. Review.

PMID:
15018895
2.

Non-angiogenic functions of VEGF in breast cancer.

Mercurio AM, Lipscomb EA, Bachelder RE.

J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):283-90. Review.

PMID:
16924371
3.

Contributions of the alpha6 integrins to breast carcinoma survival and progression.

Chung J, Mercurio AM.

Mol Cells. 2004 Apr 30;17(2):203-9. Review.

4.

Autocrine laminin-5 ligates alpha6beta4 integrin and activates RAC and NFkappaB to mediate anchorage-independent survival of mammary tumors.

Zahir N, Lakins JN, Russell A, Ming W, Chatterjee C, Rozenberg GI, Marinkovich MP, Weaver VM.

J Cell Biol. 2003 Dec 22;163(6):1397-407.

5.

Integrin (alpha 6 beta 4) regulation of eIF-4E activity and VEGF translation: a survival mechanism for carcinoma cells.

Chung J, Bachelder RE, Lipscomb EA, Shaw LM, Mercurio AM.

J Cell Biol. 2002 Jul 8;158(1):165-74. Epub 2002 Jul 8.

6.

The role of c-Src in integrin (α6β4) dependent translational control.

Soung YH, Korneeva N, Kim TH, Chung J.

BMC Cell Biol. 2013 Nov 1;14:49. doi: 10.1186/1471-2121-14-49.

7.
8.

Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primary breast cancer cultures in vitro.

Weigand M, Hantel P, Kreienberg R, Waltenberger J.

Angiogenesis. 2005;8(3):197-204. Epub 2005 Nov 19.

PMID:
16328160
9.

Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.

Peng S, Wang Y, Peng H, Chen D, Shen S, Peng B, Chen M, Lencioni R, Kuang M.

Hepatology. 2014 Oct;60(4):1264-77. doi: 10.1002/hep.27236. Epub 2014 Aug 25.

PMID:
24849467
10.

Autocrine VEGF loops, signaling pathways, and acute leukemia regulation.

Fragoso R, Elias AP, Dias S.

Leuk Lymphoma. 2007 Mar;48(3):481-8. Review.

PMID:
17454587
11.

Clinical significance of the integrin α6β4 in human malignancies.

Stewart RL, O'Connor KL.

Lab Invest. 2015 Sep;95(9):976-86. doi: 10.1038/labinvest.2015.82. Epub 2015 Jun 29. Review.

12.
13.

Mnk mediates integrin α6β4-dependent eIF4E phosphorylation and translation of VEGF mRNA.

Korneeva NL, Soung YH, Kim HI, Giordano A, Rhoads RE, Gram H, Chung J.

Mol Cancer Res. 2010 Dec;8(12):1571-8. doi: 10.1158/1541-7786.MCR-10-0091. Epub 2010 Oct 21.

14.

The alpha6beta4 integrin maintains the survival of human breast carcinoma cells in vivo.

Lipscomb EA, Simpson KJ, Lyle SR, Ring JE, Dugan AS, Mercurio AM.

Cancer Res. 2005 Dec 1;65(23):10970-6.

15.

Curcumin inhibition of the functional interaction between integrin α6β4 and the epidermal growth factor receptor.

Soung YH, Chung J.

Mol Cancer Ther. 2011 May;10(5):883-91. doi: 10.1158/1535-7163.MCT-10-1053. Epub 2011 Mar 9.

16.

Mobilization and activation of a signaling competent alpha6beta4integrin underlies its contribution to carcinoma progression.

Lipscomb EA, Mercurio AM.

Cancer Metastasis Rev. 2005 Sep;24(3):413-23. Review.

PMID:
16258729
17.

The alpha6beta4 integrin can regulate ErbB-3 expression: implications for alpha6beta4 signaling and function.

Folgiero V, Bachelder RE, Bon G, Sacchi A, Falcioni R, Mercurio AM.

Cancer Res. 2007 Feb 15;67(4):1645-52.

18.

Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway.

Kim DS, Franklyn JA, Boelaert K, Eggo MC, Watkinson JC, McCabe CJ.

J Clin Endocrinol Metab. 2006 Nov;91(11):4603-11. Epub 2006 Aug 22.

PMID:
16926250
19.

Role of α6β4 integrin in cell motility, invasion and metastasis of mammary tumors.

Soung YH, Gil HJ, Clifford JL, Chung J.

Curr Protein Pept Sci. 2011 Feb;12(1):23-9. Review.

PMID:
21190525
20.

Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias.

Dias S, Hattori K, Heissig B, Zhu Z, Wu Y, Witte L, Hicklin DJ, Tateno M, Bohlen P, Moore MA, Rafii S.

Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10857-62.

Supplemental Content

Support Center